Hepatitis C Care: Comparison of Monitoring Methods
A study analyzing US health data suggests that combining laboratory and pharmacy records provides the most accurate assessment of Hepatitis C treatment outcomes. The research highlights that relying on single data sources may lead to underestimating cure rates.
Why it matters
Improving monitoring methods is essential for public health initiatives aiming to eliminate Hepatitis C through direct-acting antiviral treatments.
COMBINING laboratory and pharmacy data provided the most rigorous measure of hepatitis C care outcomes in a US cohort study, although incomplete follow-up RNA testing meant this approach could underestimate cure. When only one data source was available, laboratory-confirmed viral clearance or pharmacy-recorded treatment initiation could serve as reasonable surrogate measures of viral clearance after treatment initiation.
Hepatitis C is a viral infection that can lead to advanced liver disease, liver cancer and death if left untreated. Direct-acting antivirals (DAAs) cure more than 95% of infections, with sustained virologic response (SVR), defined as undetectable hepatitis C virus (HCV) RNA at least 12 weeks after treatment completion, considered evidence of cure.
Healthcare systems often rely on laboratory results, pharmacy records or a combination of both to monitor treatment outcomes, making accurate measurement important for tracking progress towards hepatitis C elimination.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in